Variant allele frequency: a decision-making tool in precision oncology?

被引：41

作者：

Bielo, Luca Boscolo ^{[1
,2
]}

Trapani, Dario ^{[1
,2
]}

Repetto, Matteo ^{[1
,2
,3
]}

Crimini, Edoardo ^{[1
,2
]}

Valenza, Carmine ^{[1
,2
]}

Belli, Carmen ^{[1
]}

Criscitiello, Carmen ^{[1
,2
]}

Marra, Antonio ^{[1
]}

Subbiah, Vivek ^{[4
]}

Curigliano, Giuseppe ^{[1
,2
]}

机构：

[1] IRCCS, European Inst Oncol, Div New Drugs & Early Drug Dev Innovat Therapies, Milan, Italy

[2] Univ Milan, Dept Oncol & Hemato Oncol, Milan, Italy

[3] Mem Sloan Kettering Canc Ctr, Early Drug Dev Serv, New York, NY USA

[4] Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA

来源：

TRENDS IN CANCER | 2023年 / 9卷 / 12期

关键词：

CIRCULATING TUMOR DNA; CELL-FREE DNA; LUNG ADENOCARCINOMA; MUTATION DETECTION; CLINICAL UTILITY; EGFR-TKI; PLASMA; EFFICACY; HETEROGENEITY; ABUNDANCE;

D O I：

10.1016/j.trecan.2023.08.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Precision oncology requires additional predictive biomarkers for targeted therapy selection. Variant allele frequency (VAF), measuring the proportion of variant alleles within a genomic locus, provides insights into tumor clonality in somatic genomic testing, yielding a strong rationale for targeting dominant cancer cell populations. The prognostic and predictive roles of VAF have been evaluated across different studies. Yet, the absence of validated VAF thresholds and a lack of standardization between sequencing assays currently hampers its clinical utility. Therefore, analytical and clinical validation must be further examined. This Review summarizes the evidence regarding the use of VAF as a predictive biomarker and discusses challenges and opportunities for its clinical implementation as a decision-making tool for targeted therapy selection.

引用

页码：1058 / 1068

页数：11

共 78 条

[21] Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA [J].

Forshew, Tim ;

Murtaza, Muhammed ;

Parkinson, Christine ;

Gale, Davina ;

Tsui, Dana W. Y. ;

Kaper, Fiona ;

Dawson, Sarah-Jane ;

Piskorz, Anna M. ;

Jimenez-Linan, Mercedes ;

Bentley, David ;

Hadfield, James ;

May, Andrew P. ;

Caldas, Carlos ;

Brenton, James D. ;

Rosenfeld, Nitzan .

SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (136)

[22] Polymerase Chain Reaction [J].

Garibyan, Lilit ;

Avashia, Nidhi .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 (03) :E1-E4

[23] LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology [J].

Garrido, Pilar ;

Paz-Ares, Luis ;

Majem, Margarita ;

Moran, Teresa ;

Trigo, Jose Manuel ;

Bosch-Barrera, Joaquim ;

Garcia-Campelo, Rosario ;

Gonzalez-Larriba, Jose Luis ;

Sanchez-Torres, Jose Miguel ;

Isla, Dolores ;

Vinolas, Nuria ;

Camps, Carlos ;

Insa, Amelia ;

Juan, Oscar ;

Massuti, Bartomeu ;

Paredes, Alfredo ;

Artal, Angel ;

Lopez-Brea, Marta ;

Palacios, Jose ;

Felip, Enriqueta .

CANCER MEDICINE, 2021, 10 (17) :5878-5888

[24] Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing [J].

Gerlinger, Marco ;

Rowan, Andrew J. ;

Horswell, Stuart ;

Larkin, James ;

Endesfelder, David ;

Gronroos, Eva ;

Martinez, Pierre ;

Matthews, Nicholas ;

Stewart, Aengus ;

Tarpey, Patrick ;

Varela, Ignacio ;

Phillimore, Benjamin ;

Begum, Sharmin ;

McDonald, Neil Q. ;

Butler, Adam ;

Jones, David ;

Raine, Keiran ;

Latimer, Calli ;

Santos, Claudio R. ;

Nohadani, Mahrokh ;

Eklund, Aron C. ;

Spencer-Dene, Bradley ;

Clark, Graham ;

Pickering, Lisa ;

Stamp, Gordon ;

Gore, Martin ;

Szallasi, Zoltan ;

Downward, Julian ;

Futreal, P. Andrew ;

Swanton, Charles .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (10) :883-892

[25] EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study [J].

Gieszer, Balazs ;

Megyesfalvi, Zsolt ;

Dulai, Viktoria ;

Papay, Judit ;

Kovalszky, Ilona ;

Timar, Jozsef ;

Fillinger, Janos ;

Harko, Tunde ;

Pipek, Orsolya ;

Teglasi, Vanda ;

Regos, Eszter ;

Papp, Gergo ;

Szallasi, Zoltan ;

Laszlo, Viktoria ;

Renyi-Vamos, Ferenc ;

Galffy, Gabriella ;

Bodor, Csaba ;

Dome, Balazs ;

Moldvay, Judit .

TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (02) :662-+

[26]

Green Michael R, 2019, Cold Spring Harb Protoc, V2019, DOI 10.1101/pdb.top095109

[27] Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer [J].

Gupta, Rohan ;

Othman, Tamer ;

Chen, Chen ;

Sandhu, Jaideep ;

Ouyang, Ching ;

Fakih, Marwan .

ONCOLOGIST, 2020, 25 (03) :235-243

[28]

Hayes D.F., Oncology: an Evidence-Based Approach, P106

[29] Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers [J].

Hayes, DF ;

Bast, RC ;

Desch, CE ;

Fritsche, H ;

Kemeny, NE ;

Jessup, JM ;

Locker, GY ;

MacDonald, JS ;

Mennel, RG ;

Norton, L ;

Ravdin, P ;

Taube, S ;

Winn, RJ .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (20) :1456-1466

[30] Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood [J].

Higgins, Michaela J. ;

Jelovac, Danijela ;

Barnathan, Evan ;

Blair, Brian ;

Slater, Shannon ;

Powers, Penny ;

Zorzi, Jane ;

Jeter, Stacie C. ;

Oliver, George R. ;

Fetting, John ;

Emens, Leisha ;

Riley, Carol ;

Stearns, Vered ;

Diehl, Frank ;

Angenendt, Philipp ;

Huang, Peng ;

Cope, Leslie ;

Argani, Pedram ;

Murphy, Kathleen M. ;

Bachman, Kurtis E. ;

Greshock, Joel ;

Wolff, Antonio C. ;

Park, Ben H. .

CLINICAL CANCER RESEARCH, 2012, 18 (12) :3462-3469

← 1 2 3 4 5 6 7 8 →